[e-farmacos] Rosiglitazona: nota de la EMEA

["Madurga, Mariano" <mmadurga@agemed.es>]

Estimadas y estimados, 
 
La EMEA acaba de publicar y distribuir esta nota del Comite de Medicamentos Humanos (CHMP), informando sobre nuevas precauciones y contraindicaciones para los medicamentos con rosiglitazona:

During its January 2008 meeting, the Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a scientific opinion recommending the inclusion of a new warning stating that the use of rosiglitazone in patients with ischemic heart disease and/or peripheral arterial disease is not recommended. 

The CHMP also adopted an opinion recommending the addition of a new contraindication stating that rosiglitazone must not be used in patients with an acute coronary syndrome, such as angina or some types of myocardial infarction, because the medicine has not been studied in controlled trials in this specific patient group. 

La nota completa en: http://www.emea.europa.eu/pdfs/human/press/pr/4223208en.pdf
 
Un abrazo,

Mariano Madurga
www.AGEMED.es <http://www.AGEMED.es> 
mmadurga@agemed.es